Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420689 | 0.91 | CYP2C9 (0.72) | CYP2C9CYP2C19CYP3A4PTGER4EGLN1 | |
| SCHEMBL2402348 | 0.90 | CYP2C9 (0.68) | CYP2C9CYP2C19CYP3A4PTGER4PTGER2 | |
| SCHEMBL12294803 | 0.86 | CYP2C9 (0.65) | CYP2C9CYP2C19CYP3A4PTGER4PTGER2 | |
| SCHEMBL12295435 | 0.84 | CYP2C9 (0.68) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12295470 | 0.84 | CYP2C9 (0.71) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14770381 | 0.82 | CYP2C9 (0.66) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14761082 | 0.81 | CYP2C9 (0.83) | CYP2C9CYP2C19CYP3A4PTGER4 | |
| SCHEMBL2424806 | 0.80 | CYP2C9 (0.84) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12295656 | 0.80 | CYP2C9 (0.87) | CYP2C9CYP2C19CYP3A4PTGER4 | |
| SCHEMBL12295420 | 0.80 | CYP2C9 (0.73) | CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | claimed |
| EP-2547678-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2016-03-16 | — | — | EP | disclosed |
| EP-2547678-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2016-03-16 | — | — | EP | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| WO-2011113606-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065884-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | CYP2C9 4235/4885CYP2C19 4181/4885CYP3A4 2915/4885 |
| US-20140155387-A1 | Anti-Inflammation Compounds | NR0B1, NR0B2, NR5A2 | CYP2C9 1210/4885CYP2C19 2085/4885CYP3A4 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.